CD33 and acute myeloid leukemia: Similarly, gemtuzumab ozogamicin, an antibody–drug conjugate targeting CD33, has been approved for the treatment of acute myeloid leukemia (AML) in CD33-positive patients, demonstrating significant improvements in response rates and overall survival, particularly among elderly individuals (Figure 2) [62].